First patient treated in NorthStar/Clarity clinical trial

2018 12 11 00 02 7009 Atom Nuclear Lab 400

The first patient has been treated using NorthStar Medical Radioisotopes' electron accelerator-generated copper-67 (Cu-67) radioisotope in Clarity Pharmaceutical's U.S.-based SARTATE peptide receptor radionuclide therapy trial.

The phase I/IIa trial is investigating the use of copper-64 (Cu-64) and copper-67 (Cu-67) for treatment of neuroblastoma and neuroendocrine tumors.

Page 1 of 460
Next Page